 SYDNEY, AUSTRALIA, June 02, 2022 GLOBE NEWSWIRE -- Immutep Limited ASX: IMM; NASDAQ: IMMP Immutep or the Company, a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, will host a global webcast to discuss new data from 1st line non-small cell lung cancer NSCLC patients participating in its Phase II TACTI-002 trial including an analyst QA. 